Predicting Heart Failure With Preserved and Reduced Ejection FractionCLINICAL PERSPECTIVE

Background— Heart failure (HF) is a prevalent and deadly disease, and preventive strategies focused on at-risk individuals are needed. Current HF prediction models have not examined HF subtypes. We sought to develop and validate risk prediction models for HF with preserved and reduced ejection fraction (HFpEF, HFrEF). Methods and Results— Of 28,820 participants from 4 community-based cohorts, 982 developed incident HFpEF and 909 HFrEF during a median follow-up of 12 years. Three cohorts were combined, and a 2:1 random split was used for derivation and internal validation, with the fourth cohort as external validation. Models accounted for multiple competing risks (death, other HF subtype, and unclassified HF). The HFpEF-specific model included age, sex, systolic blood pressure, body mass index, antihypertensive treatment, and previous myocardial infarction; it had good discrimination in derivation (c-statistic 0.80; 95% confidence interval [CI], 0.78–0.82) and validation samples (internal: 0.79; 95% CI, 0.77–0.82 and external: 0.76; 95% CI: 0.71–0.80). The HFrEF-specific model additionally included smoking, left ventricular hypertrophy, left bundle branch block, and diabetes mellitus; it had good discrimination in derivation (c-statistic 0.82; 95% CI, 0.80–0.84) and validation samples (internal: 0.80; 95% CI, 0.78–0.83 and external: 0.76; 95% CI, 0.71–0.80). Age was more strongly associated with HFpEF, and male sex, left ventricular hypertrophy, bundle branch block, previous myocardial infarction, and smoking with HFrEF ( P value for each comparison ≤0.02). Conclusions— We describe and validate risk prediction models for HF subtypes and show good discrimination in a large sample. Some risk factors differed between HFpEF and HFrEF, supporting the notion of pathogenetic differences among HF subtypes.

[1]  C. Yancy,et al.  Population Risk Prediction Models for Incident Heart Failure: A Systematic Review , 2015, Circulation. Heart failure.

[2]  Georg Heinze,et al.  PSHREG: A SAS macro for proportional and nonproportional subdistribution hazards regression , 2015, Comput. Methods Programs Biomed..

[3]  A. Folsom,et al.  Heart failure risk prediction in the Multi-Ethnic Study of Atherosclerosis , 2014, Heart.

[4]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[5]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[6]  R. D. de Boer,et al.  Clinical Risk Stratification Optimizes Value of Biomarkers to Predict New-Onset Heart Failure in a Community-Based Cohort , 2014, Circulation. Heart failure.

[7]  D. Bluemke,et al.  Resting heart rate as predictor for left ventricular dysfunction and heart failure: MESA (Multi-Ethnic Study of Atherosclerosis). , 2014, Journal of the American College of Cardiology.

[8]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2014 update: a report from the American Heart Association. , 2014, Circulation.

[9]  P. Whincup,et al.  N‐terminal pro brain natriuretic peptide but not copeptin improves prediction of heart failure over other routine clinical risk parameters in older men with and without cardiovascular disease: population‐based study , 2014, European journal of heart failure.

[10]  Eric Boerwinkle,et al.  Troponin T and NT–Pro B-Type Natriuretic Peptide: A Biomarker Approach to Predict Heart Failure Risk—the Atherosclerosis Risk in Communities Study , 2014 .

[11]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[12]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[13]  C. Watson,et al.  Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. , 2013, JAMA.

[14]  R. D. de Boer,et al.  Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. , 2013, European heart journal.

[15]  I. Piña,et al.  Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association , 2013, Circulation. Heart failure.

[16]  D. Levy,et al.  Predictors of New-Onset Heart Failure: Differences in Preserved Versus Reduced Ejection Fraction , 2013, Circulation. Heart failure.

[17]  R. Califf,et al.  Predictors of Incident Heart Failure Hospitalizations Among Patients With Impaired Glucose Tolerance: Insight From the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Study , 2013, Circulation. Heart failure.

[18]  Richard Cairns,et al.  A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: an analysis of the PROactive study. , 2013, International journal of cardiology.

[19]  Michael J Pencina,et al.  Quantifying discrimination of Framingham risk functions with different survival C statistics , 2012, Statistics in medicine.

[20]  D. Levy,et al.  Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. , 2012, European heart journal.

[21]  Hanyu Ni,et al.  Prediction of Incident Heart Failure in General Practice: The Atherosclerosis Risk in Communities (ARIC) Study , 2012, Circulation. Heart failure.

[22]  B. Borlaug,et al.  Diastolic and Systolic Heart Failure Are Distinct Phenotypes Within the Heart Failure Spectrum , 2011, Circulation.

[23]  M. Drazner The Progression of Hypertensive Heart Disease , 2011, Circulation.

[24]  M. Zhan,et al.  Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. , 2010, JAMA.

[25]  Olle Melander,et al.  Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. , 2010, Journal of the American College of Cardiology.

[26]  P. Wilson,et al.  Predictors of Incident Heart Failure in a Large Insured Population: A One Million Person-Year Follow-Up Study , 2010, Circulation. Heart failure.

[27]  R. Vasan,et al.  Validation of the Health ABC Heart Failure Model for Incident Heart Failure Risk Prediction: The Cardiovascular Health Study , 2010, Circulation. Heart failure.

[28]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[29]  D. Mozaffarian,et al.  Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction: The American Heart Association's Strategic Impact Goal Through 2020 and Beyond , 2010, Circulation.

[30]  Ronald J. Prineas,et al.  The Minnesota Code Manual of Electrocardiographic Findings , 2009 .

[31]  J Michael Gaziano,et al.  Relation between modifiable lifestyle factors and lifetime risk of heart failure. , 2009, JAMA.

[32]  Daniel Levy,et al.  Relation of Disease Pathogenesis and Risk Factors to Heart Failure With Preserved or Reduced Ejection Fraction: Insights From the Framingham Heart Study of the National Heart, Lung, and Blood Institute , 2009, Circulation.

[33]  Tamara B Harris,et al.  Incident Heart Failure Prediction in the Elderly: The Health ABC Heart Failure Score , 2008, Circulation. Heart failure.

[34]  Roberto Ferrari,et al.  Left bundle branch block as a risk factor for progression to heart failure , 2007, European journal of heart failure.

[35]  C. Yancy,et al.  Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. , 2006, Journal of the American College of Cardiology.

[36]  Karl Swedberg,et al.  Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients , 2005, Circulation.

[37]  Daniel Levy,et al.  The Epidemiology of Asymptomatic Left Ventricular Systolic Dysfunction: Implications for Screening , 2003, Annals of Internal Medicine.

[38]  J. Murabito,et al.  Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study , 2002, Circulation.

[39]  R. Kronmal,et al.  Multi-Ethnic Study of Atherosclerosis: objectives and design. , 2002, American journal of epidemiology.

[40]  H. Crijns,et al.  Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND I , 2000, The American journal of cardiology.

[41]  D. Levy,et al.  Profile for estimating risk of heart failure. , 1999, Archives of internal medicine.

[42]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[43]  J. McMurray,et al.  Clinical epidemiology of heart failure: public and private health burden. , 1998, European heart journal.

[44]  L. Kuller,et al.  Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. , 1995, Annals of epidemiology.

[45]  M Lunn,et al.  Applying Cox regression to competing risks. , 1995, Biometrics.

[46]  Jeffrey J. Gaynor,et al.  On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology Data , 1993 .

[47]  Margaret S. Pepe,et al.  Inference for Events with Dependent Risks in Multiple Endpoint Studies , 1991 .

[48]  J. C. Christiansen,et al.  Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. , 1990, Circulation.

[49]  P Kligfield,et al.  Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. , 1987, Circulation.

[50]  W. Kannel,et al.  An investigation of coronary heart disease in families. The Framingham offspring study. , 1979, American journal of epidemiology.

[51]  W. Kannel,et al.  AN APPROACH TO LONGITUDINAL STUDIES IN A COMMUNITY: THE FRAMINGHAM STUDY , 1963, Annals of the New York Academy of Sciences.